Utilization of Shark Cartilage Byproducts from Fisheries for Anti-Inflammatory Biomedical Applications in LPS-Induced Mice | ||||
| Egyptian Journal of Aquatic Biology and Fisheries | ||||
| Article 46, Volume 29, Issue 4, July and August 2025, Page 835-849 PDF (673.65 K) | ||||
| DOI: 10.21608/ejabf.2025.442288 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| Agustin et al. | ||||
| Abstract | ||||
| The utilization of marine byproducts, such as shark cartilage, presents a sustainable strategy for the development of novel biomedical applications. This study investigated the anti-inflammatory potential of shark cartilage extract derived from Prionace glauca, a byproduct of fisheries, in a lipopolysaccharide (LPS)-induced mouse model of inflammation. The cartilage was processed via maceration in distilled water (1:10 b/v) at 45°C for 8 hours, and its chondroitin sulfate (CS) content was quantified using High-Performance Liquid Chromatography (HPLC), yielding an average of 2.23%. Male BALB/c mice were assigned to seven groups, including an LPS-only group, a standard CS group, a commercial supplement group (Welmove), and three dosage groups of shark cartilage extract (50, 100, and 200%). Inflammation was induced through intraperitoneal injection of LPS (1mg/ 100mL PBS), and immune responses were assessed by analyzing TNF-α and IFN-γ expression in CD4+ T cells and NK cells via flow cytometry. The extract significantly reduced the percentages of CD4⁺TNF-α⁺, CD4⁺IFN-γ⁺, and NK⁺IFN-γ⁺ cells in a dose-dependent manner (P < 0.05), with higher doses (D2 and D3) restoring cytokine expression toward baseline levels. These findings highlight the potential of shark cartilage byproducts as a valuable source of natural anti-inflammatory agents, supporting their further development in pharmaceutical and biomedical fields. | ||||
| Keywords | ||||
| Shark cartilage Byproducts; LPS; Prionace galuca; Anti-inflammatory agent | ||||
|
Statistics Article View: 116 PDF Download: 178 |
||||
